Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 572 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nonalcoholic Steatohepatitis (NASH) Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis

NCT07270601
View directory record Official record
Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease
Interventions
Verasonics NXT Data Acquisition System, Philips EPIQ Elite, EchoSense FibroScan, Philips 3T Ingenia Elition
Device
Lead sponsor
ContextVision AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

FTIH of ECC4703 in Healthy Volunteers

NCT05552274
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
ECC4703, Placebo
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 2, 2026, 3:47 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study

NCT00637520
View directory record Official record
Conditions
Insulin Resistance, Nonalcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 2, 2026, 3:47 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

NCT01703260
View directory record Official record
Conditions
Nonalcoholic Steatohapatitis
Interventions
Roflumilast, Pioglitazone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Coronado, California • Annapolis, Maryland • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD

NCT03744182
View directory record Official record
Conditions
NAFLD
Interventions
HM15211, Placebo of HM15211
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 2, 2026, 3:47 PM EDT
Terminated Phase 2 Interventional Results available

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

NCT01672879
View directory record Official record
Conditions
Liver Fibrosis Due to NASH
Interventions
Placebo, SIM
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
41
States / cities
Phoenix, Arizona • Coronado, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 2, 2026, 3:47 PM EDT
Completed No phase listed Observational

Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis

NCT05357352
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Interventions
NAFLD/NASH
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 2, 2026, 3:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04565717
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, NASH
Interventions
ALN-HSD, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of an RBAC Supplement (BRM4) on NAFLD

NCT02568787
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
rice bran arabinoxylan compound (RBAC), Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Not applicable Interventional

Effect of Dietary Macronutrient Composition

NCT01371396
View directory record Official record
Conditions
Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Low-fat diet, Low-carbohydrate diet
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis

NCT03656068
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Fatty Liver, Fibrosis, Liver, Compensated Cirrhosis
Interventions
Nitazoxanide 500mg BID
Drug
Lead sponsor
Pinnacle Clinical Research, PLLC
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Conditionally Increased Output (CIO) Enhanced Ultrasound System

NCT05792423
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fatty Liver
Interventions
GE ultrasound system with increased acoustic output settings
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

NCT04091061
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
PF-06865571 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Phase 3 Interventional

Development of a Breath Test for Monitoring Patients With Liver Disease

NCT00244569
View directory record Official record
Conditions
Fatty Liver, Cirrhosis
Interventions
13C-Methacetin, Breath ID Machine
Drug · Device
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 2, 2026, 3:47 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

NCT03884075
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Interventions
Semaglutide
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Phase 1Phase 2 Interventional

Fatty Liver Disease in Obese Children

NCT02117700
View directory record Official record
Conditions
Obesity, Nonalcoholic Fatty Liver Disease, Cardiovascular Disease
Interventions
N-acetyl cysteine 600 mg once/day, N-acetyl cysteine 600mg twice/day, Placebo twice/day
Dietary Supplement · Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 2, 2026, 3:47 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02704403
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions
Elafibranor, Placebo
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
153
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Not applicable Interventional Results available

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

NCT01285362
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Fish Oil Supplementation, Placebo Supplementation
Drug
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production

NCT01262326
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Calorie and Carbohydrate Restriction
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

NCT02217475
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Cenicriviroc, Placebo
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
40
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 2, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

NCT03763877
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
PXL770, Placebo Oral Capsule
Drug
Lead sponsor
Poxel SA
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Los Angeles, California • Gainesville, Florida • Ocoee, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 2, 2026, 3:47 PM EDT
Terminated No phase listed Observational

Genetic Studies of Non-Alcoholic Fatty Liver Disease

NCT01629095
View directory record Official record
Conditions
Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
San Francisco, California • Bethesda, Maryland • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 2, 2026, 3:47 PM EDT
Recruiting Phase 3 Interventional

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions
Survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
165
States / cities
Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 2, 2026, 3:47 PM EDT
Terminated Phase 2 Interventional Results available

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

NCT05211284
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Saroglitazar Magnesium 4 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 2, 2026, 3:47 PM EDT